X0306 4 2022-06-03 false 0001710072 Edgewise Therapeutics, Inc. EWTX 0001191702 MOORE JOHN R C/O EDGEWISE THERAPEUTICS, INC. 3145 COLORADO AVE BOULDER CO 80303 false true false false General Counsel Common Stock 2022-06-03 4 M false 15230.00 1.93 A 18230.00 D Common Stock 2022-06-03 4 S false 15230.00 6.0537 D 3000.00 D Common Stock 2022-06-06 4 M false 13934.00 1.93 A 16934.00 D Common Stock 2022-06-06 4 S false 13934.00 6.0345 D 3000.00 D Common Stock 2022-06-07 4 M false 973.00 1.93 A 3973.00 D Common Stock 2022-06-07 4 S false 973.00 6.605 D 3000.00 D Common Stock 2022-06-07 4 M false 17150.00 0.71 A 20150.00 D Common Stock 2022-06-07 4 S false 17150.00 6.605 D 3000.00 D Stock Option (Right to Buy) 1.93 2022-06-03 4 M false 15230.00 0.00 D 2030-12-15 Common Stock 15230.00 211828.00 D Stock Option (Right to Buy) 1.93 2022-06-06 4 M false 13934.00 0.00 D 2030-12-15 Common Stock 13934.00 197894.00 D Stock Option (Right to Buy) 1.93 2022-06-07 4 M false 973.00 0.00 D 2030-12-15 Common Stock 973.00 196921.00 D Stock Option (Right to Buy) 0.71 2022-06-07 4 M false 17150.00 0.00 D 2030-09-01 Common Stock 17150.00 188172.00 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022. Includes 1,438 shares purchased on May 16, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.18, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.01 to $6.91, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date. 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. /s/ John R. Moore 2022-06-07